Asco Ltd.

Ym Biosciences Reports Positive Nimotuzumab Four-year Survival Data Presented At Astro 2009.(Clinical report)
Cancer Weekly; 11/17/2009; 1534 words; ...to 30-month survival data presented at ASCO 2009 and demonstrate that the benefit of...evaluable. The trial was sponsored by Biocon Ltd., the licensee from CIMAB S.A. for...from this trial was presented at the 2009 ASCO Annual Meeting and is entitled: "A Phase...

YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS.
PR Newswire; 11/11/2009; 3922 words; ...our proposal to merge Cytopia Ltd., an Australian clinical...licensees. - Daiichi Sankyo Co., Ltd., CIMYM's licensee for nimotuzumab...this trial that was released at ASCO in 2008 was expanded on at the...patients. - Innogene Kalbiotech PTE Ltd. (IGK), CIMYM's licensee...

Cell Therapeutics, Novuspharma Merging In $236M Stock Exchange.
BIOWORLD Today; 11/4/2009; 1616 words; ...Bianco also is optimistic about Xyotax. "By ASCO of next year, we could be in the enviable position...company after the merger of F. Hoffman-La Roche Ltd., of Basel, Switzerland, and Corange Ltd., of Hamilton, Bermuda. It's traded on the...

GlycoDesign Ends GD0039 Trials, Moving Focus To Other Programs.
BIOWORLD Today; 11/4/2009; 1025 words; ...American and [French] trials for renal cancer, this past week at ASCO we found out that we are seeing toxicity," said Sheri Zernentsch...studies in the UK and is partnered with Leo Pharmaceutical Products Ltd., of Denmark. Possible indications are the prevention of deep...

ImClone's Phase III Erbitux Trial In NSCLC Fails To Hit Endpoint.
BIOWORLD Today; 11/3/2009; 1417 words; ...Clinical Oncology. Results disclosed at ASCO indicated Avastin might work better given...sponsored by partner F. Hoffmann-La Roche Ltd., of Basel, Switzerland, showed Avastin...wrote in a research note at the time of the ASCO data that any decline in dosage as a result...